Zacks Investment Research
25 Jun 2026, 12:51 UTC · 1h ago
Silence Therapeutics (SLN) Surges 26.0%: Is This an Indication of Further Gains?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
25 Jun 2026, 12:51 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Silence Therapeutics (SLN) shares surged 26% to $9.16 in the last trading session on high volume. — A significant single-day price jump on high volume indicates strong short-term bullish momentum for the stock.
+0.40Silence Therapeutics expects revenue of $3.14 million for the upcoming quarter, a 1325% increase year-over-year. — Explosive revenue growth is a strong fundamental signal, although the company remains loss-making.
+0.30Topline results for Silence Therapeutics' SANRECO phase II study for divesiran are expected in August 2026. — Clinical trial results are primary catalysts for biotech valuations, creating a specific future date for high volatility.
+0.20Continue reading
6 related stories
Search tags
Silence Therapeutics is expected to report a quarterly loss of $0.32 per share, a 40.7% increase year-over-year. — Increasing losses can weigh on sentiment, though typical for early-stage biotech firms.
Which stocks this story touches
Shares rose 26% on encouraging clinical data for its lead candidate and significant expected revenue growth.
The stock closed slightly higher and has shown a modest positive return over the past month.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Finbold
2h ago
